var data={"title":"Ketorolac (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ketorolac (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389799?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ketorolac-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ketorolac (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=ketorolac-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ketorolac (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8320258\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following intravenous (IV) or intramuscular (IM) dosing of ketorolac, if necessary. The total combined duration of use of ketorolac tablets and injection should not exceed 5 days.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is not indicated for use in pediatric patients and is not indicated for minor or chronic painful conditions. Increasing the dose of ketorolac beyond labeled recommendations will not provide better efficacy but will increase the risk of developing serious adverse events. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiovascular thrombotic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal anti-inflammatory drugs (NSAIDs)  cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious gastrointestinal  bleeding, ulceration, and perforation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">NSAIDs cause an increased risk of serious  gastrointestinal (GI) events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac is contraindicated in patients with active peptic ulcer disease, recent GI bleeding or perforation, and a history of peptic ulcer disease or GI bleeding. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Intrathecal or epidural administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is contraindicated for intrathecal or epidural administration due to its alcohol content.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity reactions, ranging from bronchospasm to anaphylactic shock, have occurred and appropriate counteractive measures must be available when administering the first dose of ketorolac injection. Ketorolac is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac or allergic manifestations to aspirin or other NSAIDs.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal risk:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of bleeding:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, and those at high risk of bleeding.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is contraindicated as a prophylactic analgesic before any major surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Labor and delivery:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is contraindicated in labor and delivery because it may adversely affect fetal circulation and inhibit uterine contractions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concomitant use with NSAIDs: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Special populations:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Adjust dosage for patients 65 years and older, weighing less than 50 kg (110 lbs), and with moderately elevated serum creatinine. Doses of ketorolac injection are not to exceed 60 mg (total dose per day) in these patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49214910\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ReadySharp Ketorolac</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345791\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Ketorolac Injectable;</li>\n      <li>Ketorolac Tromethamine Injection, USP;</li>\n      <li>Toradol;</li>\n      <li>Toradol IM</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8347268\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Nonopioid;</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8349402\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pain management (acute; moderately severe) in patients &ge;50 kg: </b> <b>Note:</b> The maximum combined duration of treatment (for parenteral and oral) is 5 days; do not increase dose or frequency; supplement with low-dose opioids if needed for breakthrough pain. Oral formulation should not be given as an initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 60 mg as a single dose or 30 mg every 6 hours (maximum: 120 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 30 mg as a single dose or 30 mg every 6 hours (maximum: 120 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM, IV: Critically-ill patients (off-label dose): 30 mg once, followed by 15 to 30 mg every 6 hours for up to 5 days (maximum: 120 mg/day) (Barr 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 20 mg, followed by 10 mg every 4 to 6 hours as needed; maximum: 40 mg/day; oral dosing is intended to be a continuation of IM or IV therapy only</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: Initial: 10 mg to 30 mg as a single dose and then every 4 to 6 hours as needed (maximum: 120 mg/day) for up to 2 days; lowest effective dose should be utilized</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 10 mg every 4 to 6 hours as needed (maximum: 40 mg/day); therapy should not exceed 5 days for postoperative pain and 7 days for musculoskeletal pain</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Conversion from IM to oral: Total combined dose (IM and oral) should not exceed 120 mg/day on the day of conversion; oral dose should not exceed 40 mg/day on subsequent days. When used as a continuation of IM therapy, total duration of therapy (IM and oral) should not exceed 5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment for low body weight (&lt;50 kg):</b> Refer to geriatric dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8349401\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ketorolac-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ketorolac (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Pain management (acute; moderately severe):</b> Adolescents &ge;17 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8349403\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pain management (acute; moderately severe): </b> Adults &ge;65 years: <b>Note:</b> May have an increased incidence of GI bleeding, ulceration, and perforation. The maximum combined duration of treatment (for parenteral and oral) is 5 days. Oral formulation should not be given as an initial dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 30 mg as a single dose or 15 mg every 6 hours (maximum: 60 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 15 mg as a single dose or 15 mg every 6 hours (maximum: 60 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 10 mg, followed by 10 mg every 4 to 6 hours  as needed; maximum: 40 mg/day; oral dosing is intended to be a continuation of IM or IV therapy only</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM:  Initial: 10 mg as a single dose and then the lowest effective dose every 4 to 6 hours as needed; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Refer to adult dosing; lowest effective dose is recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8350484\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Mild to moderate impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">IM: 30 mg as a single dose or 15 mg every 6 hours (maximum: 60 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">IV: 15 mg as a single dose or 15 mg every 6 hours (maximum: 60 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Oral: 10 mg, followed by 10 mg every 4 to 6 hours as needed; maximum: 40 mg/day; oral dosing is intended to be a continuation of IM or IV therapy only</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">\n      <b>Note:</b> The maximum combined duration of treatment (for parenteral and oral) is 5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Advanced impairment or patients at risk for renal failure due to volume depletion: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Dialysis: Not readily dialyzable due to high protein binding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serum creatinine: 1.9 mg/dL to 5 mg/dL (170 micromol/L to 442 micromol/L): IM: Reduce dose by 50%; maximum: 60 mg/day. Use with caution and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serum creatinine: &gt;5 mg/dL (&gt;442 micromol/L): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> The maximum combined duration of treatment (for parenteral and oral) is 5 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8350485\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution, may cause elevation of liver enzymes; discontinue if clinical signs and symptoms of liver disease develop.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment: No dosage adjustment necessary; use with caution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment or active hepatic disease: Use is contraindicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8353206\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection, as tromethamine: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ReadySharp Ketorolac: 15 mg/mL [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as tromethamine: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL); 60 mg/2 mL (2 mL); 300 mg/10 mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as tromethamine [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg/mL (1 mL); 30 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular, as tromethamine: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular, as tromethamine [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as tromethamine: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345793\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345784\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg==&amp;TOPIC_ID=9152\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8352025\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May administer with food to reduce GI upset.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer slowly and deeply into the muscle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer IV bolus over a minimum of 15 seconds.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345794\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>US labeling:</i> Short-term (&le;5 days) management of moderate to severe acute pain requiring analgesia at the opioid level</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Short-term (&le;5 days) management of moderate to moderately severe acute pain following surgery (eg, dental, general, or orthopaedic surgery); short-term (&le;7 days) management of moderate to moderately severe acute musculoskeletal pain (eg, pain associated with trauma, post-partum uterine cramping)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection: Short-term (&le;2 days) management of moderate to severe acute pain following major surgery (eg, major abdominal, orthopaedic, or gynecologic procedures)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25881884\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Migraine (adults) (intramuscular); Migraine (adults) (intravenous)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8320263\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ketorolac may be confused with Ketalar, methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Toradol may be confused with Foradil, Inderal, TEGretol, traMADol, tromethamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Ketorolac is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to an increased risk of GI bleeding, peptic ulcer disease, and acute kidney injury. May increase risk of acute kidney injury and further decline of kidney function in elderly patients with stages IV or higher chronic kidney disease or CrCl less than 30 mL/minute (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Ketorolac is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Toradol [Canada and multiple international markets] may be confused with Theradol brand name for tramadol [Netherlands]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8346957\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Frequencies noted for parenteral administration:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal pain (13%), dyspepsia (12%), nausea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (4%), hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (7%), drowsiness (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (7%), constipation, flatulence, gastrointestinal fullness, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer, heartburn, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, prolonged bleeding time, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormality in thinking, acute pancreatitis, acute renal failure, agranulocytosis, alopecia, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, aplastic anemia, aseptic meningitis, asthma, azotemia, blurred vision, bradycardia, bronchospasm, bruise, cardiac arrhythmia, cardiac failure, chest pain, cholestatic jaundice, coma, confusion, conjunctivitis, cough, cystitis, depression, dyspnea, dysuria, eosinophilia, epistaxis, eructation, erythema multiforme, esophagitis, euphoria, exacerbation of urinary frequency, exfoliative dermatitis, extrapyramidal reaction, fever, flank pain, flushing, gastritis, glossitis, hallucination, hearing loss, hematemesis, hematuria, hemolytic anemia, hemolytic-uremic syndrome, hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hyperglycemia, hyperkalemia, hyperkinesis, hypersensitivity reaction, hyponatremia, hypotension, increased susceptibility to infection, increased thirst, infertility, inflammatory bowel disease, insomnia, interstitial nephritis, jaundice, lack of concentration, laryngeal edema, leukopenia, lymphadenopathy, maculopapular rash, melena, myocardial infarction, nephritis, nervousness, oliguria, pallor, palpitations, pancytopenia, paresthesia, pneumonia, polyuria, proteinuria, psychosis, pulmonary edema, rectal hemorrhage, renal failure, respiratory depression, rhinitis, seizure, sepsis, skin photosensitivity, Stevens-Johnson syndrome, stomatitis (ulcerative), stupor, syncope, tachycardia, thrombocytopenia, tongue edema, toxic epidermal necrolysis, tremor, urinary retention, urticaria, vasculitis, vertigo, weakness, weight gain, wound hemorrhage (postoperative), xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345801\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ketorolac, aspirin, other NSAIDs, or any component of the formulation; active or history of peptic ulcer disease; recent or history of GI bleeding or perforation; history of  asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; advanced renal disease or risk of renal failure (due to volume depletion); prophylactic analgesic before any major surgery; suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding; concurrent use with  aspirin, other NSAIDs, probenecid, or pentoxifylline; epidural or intrathecal administration (injection only); use in the setting of coronary artery bypass graft (CABG) surgery; labor and delivery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling):  Intraoperative use; coagulation disorders; active GI bleeding; postoperative patients with high-bleeding risk; severe uncontrolled heart failure; inflammatory bowel disease; severe hepatic impairment or active hepatic disease; moderate to severe renal impairment (serum creatinine &gt;442 micromol/L and/or creatinine clearance &lt;30 mL/minute) or deteriorating renal; known hyperkalemia; third trimester of pregnancy; breast-feeding; use in children and adolescents &lt;18 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345802\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: <b>[US Boxed Warning]: Inhibits platelet function; contraindicated in patients with cerebrovascular bleeding (suspected or confirmed), hemorrhagic diathesis, incomplete hemostasis and patients at high risk for bleeding.</b> Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events:<b>[US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including MI and stroke. Risk may occur early during treatment and may increase with duration of use.</b> Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of serious cardiovascular thrombotic events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors and in those receiving higher doses. New onset hypertension or exacerbation of hypertension may occur (NSAIDs may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention, use with caution in patients with edema. Avoid use in heart failure (ACCF/AHA [Yancy 2013]). Avoid use in patients with a recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI events:<b> [US Boxed Warning]: NSAIDs cause increased risk of serious GI inflammation, ulceration, bleeding, and perforation (may be fatal); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk of serious GI events. These events may occur at any time during therapy and without warning.</b> Avoid use in patients with active GI bleeding. In patients with a history of acute lower GI bleeding, avoid use of non-aspirin NSAIDs, especially if due to angioectasia or diverticulosis (Strate 2016). Use caution with a history of GI ulcers, inflammatory bowel disease, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of GI complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare (sometimes fatal) severe hepatic reactions (eg, jaundice, fulminant hepatitis, hepatic necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if signs or symptoms of hepatic disease develop or if systemic manifestations occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: <b>[US Boxed Warning]: Ketorolac injection is contraindicated in patients with prior hypersensitivity reaction to aspirin or NSAIDs.</b> Even in patients without prior exposure, hypersensitivity including bronchospasm and anaphylactic shock, may occur; patients with &quot;aspirin triad&quot; (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow, which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Acute renal failure, interstitial nephritis, and nephrotic syndrome have been reported with ketorolac use; papillary necrosis and renal injury have been reported with long-term use of NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: NSAIDs may cause potentially fatal serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first sign of skin rash (or any other hypersensitivity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery bypass graft surgery/major surgery: <b>[US Boxed Warning]: Use is contraindicated as prophylactic analgesic before any major surgery and is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</b> Risk of MI and stroke may be increased with use following CABG surgery. Wound bleeding and postoperative hematomas have been associated with ketorolac use in the perioperative setting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment or a history of hepatic disease; patients with advanced hepatic disease are at an increased risk of GI bleeding with NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.</b> Use with caution in patients with renal impairment or history of kidney disease. Dosage adjustment is required in patients with moderate elevation in serum creatinine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspirin/other NSAIDs: <b>[US Boxed Warning]: Concurrent use of ketorolac with aspirin or other NSAIDs is contraindicated due to the increased risk of adverse reactions.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: <b>[US Boxed Warning]: Dosage adjustment is required for patients &ge;65 years of age.</b> Elderly patients are at greater risk for serious GI, cardiovascular, and/or renal adverse events; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Labor and delivery: <b>[US Boxed Warning]: Ketorolac is contraindicated during labor and delivery (may inhibit uterine contractions and adversely affect fetal circulation). </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Low body weight: <b>[US Boxed Warning]: Dosage adjustment is required for patients weighing &lt;50 kg (&lt;110 pounds).</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric:<b> [US Boxed Warning]: Ketorolac is not indicated for use in pediatric patients.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral: <b>[US Boxed Warning]: Oral therapy is only indicated for use as continuation treatment, following parenteral ketorolac and is not indicated for minor or chronic painful conditions.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral/injection: <b>[US Boxed Warning]: Systemic ketorolac is indicated for short term (&le;5 days) use in adults for treatment of moderately severe acute pain requiring opioid-level analgesia. Do not exceed maximum daily recommended doses; does not improve efficacy but may increase the risk of serious adverse effects.</b> The combined therapy duration (oral and parenteral) should not exceed 5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: <b>[US Boxed Warning]: Ketorolac injection is contraindicated for epidural or intrathecal administration (formulation contains alcohol). </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299558\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8347281\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9152&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Ketorolac (Systemic) may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Ketorolac (Systemic) may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Ketorolac (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pelubiprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: Ketorolac (Systemic) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Ketorolac (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b> Exceptions: </b>Choline Magnesium Trisalicylate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaltoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8349365\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">High-fat meals may delay time to peak (by ~1 hour) and decrease peak concentrations. Management: Administer tablet with food or milk to decrease gastrointestinal distress.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345796\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345797\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[U.S. Boxed Warning]: Ketorolac is contraindicated during labor and delivery (may inhibit uterine contractions and adversely affect fetal circulation).</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Ketorolac crosses the placenta (Walker 1988). Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013). Because they may cause premature closure of the ductus arteriosus, the use of NSAIDs late in pregnancy should be avoided.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in women having difficulty conceiving or those undergoing investigation of fertility. The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bloor 2013; Bermas 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8345800\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ketorolac is present in breast milk (Wischnik 1989).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of ketorolac is 0.21% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 40 mg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000). Using the highest milk concentration (7.9 ng/mL), the estimated daily infant dose via breast milk is 1.185 mcg/kg/day. This milk concentration was obtained following maternal administration of oral ketorolac 10 mg four times a day for 2 days in women 2 to 6 days postpartum (Wischnik 1989).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, NSAIDs may be used in postpartum women who wish to breastfeed; however, agents other than ketorolac are preferred (Montgomery 2012) and use should be avoided in women breastfeeding infants with platelet dysfunction or thrombocytopenia (Bloor 2013; Sammaritano 2014). The manufacturer recommends that caution be used if administered to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8350489\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administer tablet with food or milk to decrease gastrointestinal distress.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8352030\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (serum creatinine, BUN, urine output); CBC and platelets, liver function tests; chemistry profile; blood pressure; observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8349372\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum concentration: Therapeutic: 0.3-5 mcg/mL; Toxic: &gt;5 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8349370\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8349373\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Analgesic: Oral: 30-60 minutes; IM, IV: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Analgesic: Oral: 2 to 3 hours; IM, IV: &le;2-3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Analgesic: 4-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed (100%); IM: Rapid and complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Poor penetration into CSF; V<sub>d</sub> beta:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4-8 years: 0.19-0.44 L/kg (mean: 0.26 L/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 0.11-0.33 L/kg (mean: 0.18 L/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; undergoes hydroxylation and glucuronide conjugation; in children 4-8 years, V<sub>dss</sub> and plasma clearance were twice as high as adults </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral, IM: 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 6-18 months of age (n=25): S-enantiomer: 0.83 &plusmn; 0.7 hours; R-enantiomer: 4 &plusmn; 0.8 hours (Lynn 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1-16 years (n=36): Mean: 3 &plusmn; 1.1 hours (Dsida 2002) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">3-18 years (n=24): Mean: 3.8 &plusmn; 2.6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">4-8 years (n=10): Mean: ~6 hours; Range: 3.5-10 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mean: ~5 hours; Range: 2-9 hours [S-enantiomer ~2.5 hours (biologically active); R-enantiomer ~5 hours]; Prolonged 30% to 50% in elderly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">With renal impairment: S<sub>cr</sub> 1.9-5 mg/dL: Mean: ~11 hours; Range: 4-19 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Renal dialysis patients: Mean: ~14 hours; Range: 8-40 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: ~45 minutes; IM: 30-60 minutes; IV: 1-3 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (92%, ~60% as unchanged drug); feces ~6%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8353221\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (ReadySharp Ketorolac Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/mL (1): $265.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ketorolac Tromethamine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/mL (1 mL): $1.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/mL (1 mL): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/2 mL (2 mL): $1.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ketorolac Tromethamine Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/2 mL (2 mL): $1.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ketorolac Tromethamine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $215.71</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961984\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Altrom (EC);</li>\n      <li>Analac (TW, VN);</li>\n      <li>Arolak (BD);</li>\n      <li>Arvolac (PH);</li>\n      <li>Bedoral (ZA);</li>\n      <li>Bonket (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Dilox (CL);</li>\n      <li>Dolac (BF, BJ, CI, ET, GH, GM, GN, ID, KE, LR, MA, ML, MR, MU, MW, NE, NG, RU, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Dolgenal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Dolorex (PE);</li>\n      <li>Dolorex Gel (PE);</li>\n      <li>Dolten (AR, PY);</li>\n      <li>Eleadol (UY);</li>\n      <li>Erphapain (ID);</li>\n      <li>Eurolac (PH);</li>\n      <li>Farpain (ID);</li>\n      <li>Inco (TW);</li>\n      <li>Kelac (IN);</li>\n      <li>Kenalgesic (CO);</li>\n      <li>Keromin (KR);</li>\n      <li>Ketanov (IN, LV, PH, RO);</li>\n      <li>Keto (HK, ID, MY, PH, SG);</li>\n      <li>Ketobet (PH);</li>\n      <li>Ketogesic (VN);</li>\n      <li>Ketolac (TH);</li>\n      <li>Ketomed (PH);</li>\n      <li>Ketonort (UA);</li>\n      <li>Ketoracin (KR);</li>\n      <li>Ketoral (AU);</li>\n      <li>Ketoro (TW);</li>\n      <li>Ketorol (LK, RO, UA);</li>\n      <li>Ketosic (ID);</li>\n      <li>Ketron (CO);</li>\n      <li>Kine (PE);</li>\n      <li>Korac (BD);</li>\n      <li>Kortezor (PH);</li>\n      <li>Minolac (BD);</li>\n      <li>Ni Song (CN);</li>\n      <li>Nomadol (EC);</li>\n      <li>Notolac (EC, VE);</li>\n      <li>Ocudol (VE);</li>\n      <li>Oradol (PH);</li>\n      <li>Painoff (TW);</li>\n      <li>Poenkerat (PY);</li>\n      <li>Rapix (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Remopain (ID);</li>\n      <li>Rolac (LK);</li>\n      <li>Rolesen (EC);</li>\n      <li>Scelto (ID);</li>\n      <li>Supradol (DO, PA, SV);</li>\n      <li>Tabel (KR);</li>\n      <li>Taradyl (BE);</li>\n      <li>Teromac (PH);</li>\n      <li>Tora-Dol (CH);</li>\n      <li>Toradol (AE, AU, BH, CY, DK, EC, EG, ES, FI, HK, ID, IQ, IR, IS, IT, JO, KW, LB, LY, NO, OM, PH, PK, QA, SA, SE, SY, YE);</li>\n      <li>Toramed (PH);</li>\n      <li>Toramine (ID);</li>\n      <li>Torasic (ID);</li>\n      <li>Torotas (PH);</li>\n      <li>Torpain (ID);</li>\n      <li>Tral (PH);</li>\n      <li>Trolac (ID, KR);</li>\n      <li>Winop (BD);</li>\n      <li>Xevolac (PH, TH);</li>\n      <li>Zerodol (BR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balevi B, &quot;Ketorolac Versus Ibuprofen: A Simple Cost-Efficacy Comparison for Dental Use,&quot; <i>J Can Dent Assoc</i>, 1994, 60(1):31-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/8293359/pubmed\" target=\"_blank\" id=\"8293359\">8293359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo; <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/21640290/pubmed\" target=\"_blank\" id=\"21640290\">21640290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/24663106/pubmed\" target=\"_blank\" id=\"24663106\">24663106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>J Am Coll Cardiol</i>, 2008, 52(18):1502-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/23558845/pubmed\" target=\"_blank\" id=\"23558845\">23558845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buck ML, &ldquo;Clinical Experience With Ketorolac in Children,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(9):1009-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/7803871/pubmed\" target=\"_blank\" id=\"7803871\">7803871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buckley MM and Brogden RN, &quot;Ketorolac. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential,&quot; <i>Drugs</i>, 1990, 39(1):86-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/2178916/pubmed\" target=\"_blank\" id=\"2178916\">2178916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo; <i>J Am Coll Cardiol</i>, 2005, 45(8):1295-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/15837265/pubmed\" target=\"_blank\" id=\"15837265\">15837265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo; <i>N Engl J Med</i>, 2001, 345(25):1809-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/11752357/pubmed\" target=\"_blank\" id=\"11752357\">11752357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo; <i>Age Ageing</i>, 1984, 13(2):120-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/6731166/pubmed\" target=\"_blank\" id=\"6731166\">6731166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo; <i>Hypertension</i>, 2000, 36(3):461-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/10988282/pubmed\" target=\"_blank\" id=\"10988282\">10988282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dsida RM, Wheeler M, Birmingham PK, et al, &quot;Age-Stratified Pharmacokinetics of Ketorolac Tromethamine in Pediatric Surgical Patients,&quot; <i>Anesth Analg</i>, 2002, 94(2):266-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/11812682/pubmed\" target=\"_blank\" id=\"11812682\">11812682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ericson A and K&auml;ll&eacute;n BA, &quot;Nonsteroidal Anti-Inflammatory Drugs in Early Pregnancy,&quot; <i>Reprod Toxicol</i>, 2001, 15(4):371-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/ 11489592 /pubmed\" target=\"_blank\" id=\" 11489592 \"> 11489592 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forbes JA, Butterworth GA, Burchfield WH, et al, &quot;Evaluation of Ketorolac, Aspirin, and an Acetaminophen-Codeine Combination in Postoperative Oral Surgery Pain,&quot; <i>Pharmacotherapy</i>, 1990, 10(6 Pt 2):77S-93S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/2082317/pubmed\" target=\"_blank\" id=\"2082317\">2082317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forbes JA, Kehm CJ, Grodin CD, et al, &quot;Evaluation of Ketorolac, Ibuprofen, Acetaminophen, and an Acetaminophen-Codeine Combination in Postoperative Oral Surgery Pain,&quot; <i>Pharmacotherapy</i>, 1990, 10(6 Pt 2):94S-105S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/2082318/pubmed\" target=\"_blank\" id=\"2082318\">2082318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fricke JR Jr, Angelocci D, Fox K, et al, &quot;Comparison of the Efficacy and Safety of Ketorolac and Meperidine in the Relief of Dental Pain,&quot; <i>J Clin Pharmacol</i>, 1992, 32(4):376-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/1569240/pubmed\" target=\"_blank\" id=\"1569240\">1569240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fricke J, Halladay SC, Bynum L, et al, &quot;Pain Relief After Dental Impaction Surgery Using Ketorolac, Hydrocodone Plus Acetaminophen, or Placebo,&quot; <i>Clin Ther</i>, 1993, 15(3):500-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/8364942/pubmed\" target=\"_blank\" id=\"8364942\">8364942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerstenfeld LC, Thiede M, Seibert K, et al, &ldquo;Differential Inhibition of Fracture Healing by Non-Selective and Cyclooxygenase-2 Selective Non-Steroidal Anti-Inflammatory Drugs,&rdquo; <i>J Orthop Res</i>, 2003, 21(4):670-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/12798067/pubmed\" target=\"_blank\" id=\"12798067\">12798067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo; <i>Arch Intern Med</i>, 1998, 158(10):1108-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/9605782/pubmed\" target=\"_blank\" id=\"9605782\">9605782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jallad NS, Garg DC, Martinez JJ, et al, &ldquo;Pharmacokinetics of Single-Dose Oral and Intramuscular Ketorolac Tromethamine in the Young and Elderly,&rdquo; <i>J Clin Pharmacol</i>, 1990, 30(1):76-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/2303585/pubmed\" target=\"_blank\" id=\"2303585\">2303585</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joishy SK and Walsh D, &ldquo;The Opioid-Sparing Effects of Intravenous Ketorolac as an Adjuvant Analgesic in Cancer Pain: Application in Bone Mestastases and the Opioid Bowel Syndrome,&rdquo; <i>J Pain Symptom Manage</i>, 1998, 16(5):334-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/9846029/pubmed\" target=\"_blank\" id=\"9846029\">9846029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ketorolac tromethamine injection [prescribing information]. Schaumburg, IL: Athenax; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ketorolac tromethamine tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li DK, Liu L, and Odouli R, &quot;Exposure to Non-Steroidal Anti-Inflammatory Drugs During Pregnancy and Risk of Miscarriage: Population Based Cohort Study,&quot;<i> BMJ</i>, 2003, 327(7411):368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/12919986/pubmed\" target=\"_blank\" id=\"12919986\">12919986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Litalien C and Jacqz-Aigrain E, &ldquo;Risks and Benefits of Nonsteroidal Anti-inflammatory Drugs in Children: A Comparison With Paracetamol,&rdquo; <i>Paediatr Drugs</i>, 2001, 3(11):817-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/11735667/pubmed\" target=\"_blank\" id=\"11735667\">11735667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lynn AM, Bradford H, Kantor ED, et al, &quot;Postoperative Ketorolac Tromethamine Use in Infants Aged 6-18 Months: The Effect on Morphine Usage, Safety Assessment, and Stereo-Specific Pharmacokinetics,&quot; <i>Anesth Analg</i>, 2007, 104(5):1040-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/17456651/pubmed\" target=\"_blank\" id=\"17456651\">17456651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marret E, Flahault A, Samama CM, et al, &ldquo;Effects of Postoperative, Nonsteroidal, Antiinflammatory Drugs on Bleeding Risk After Tonsillectomy: Meta-Analysis of Randomized, Controlled Trials,&rdquo; <i>Anesthesiology</i>, 2003, 98(6):1497-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/12766664/pubmed\" target=\"_blank\" id=\"12766664\">12766664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maunuksela E, Kokki H, and Bullingham RES, &ldquo;Comparison of Intravenous Ketorolac With Morphine for Postoperative Pain in Children,&rdquo; <i>Clin Pharmacol Ther</i>, 1992, 52(4):436-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/1424417/pubmed\" target=\"_blank\" id=\"1424417\">1424417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moise KJ Jr, &quot;Effect of Advancing Gestational Age on the Frequency of Fetal Ductal Constriction in Association With Maternal Indomethacin Use,&quot; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1350-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/ 8498410 /pubmed\" target=\"_blank\" id=\" 8498410 \"> 8498410 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo; <i>Am J Hypertens</i>, 2000, 13(11):1161-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/11078175/pubmed\" target=\"_blank\" id=\"11078175\">11078175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Munro HM, Reigger LQ, Reynolds PI, et al, &ldquo;Comparison of the Analgesic and Emetic Properties of Ketorolac and Morphine for Paediatric Outpatient Strabismus Surgery,&rdquo; <i>Br J Anaesth</i>, 1994, 72(6):624-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/8024908/pubmed\" target=\"_blank\" id=\"8024908\">8024908</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nielsen GL, S&oslash;rensen HT, Larsen H, et al, &quot;Risk of Adverse Birth Outcome and Miscarriage in Pregnant Users of Non-Steroidal Anti-Inflammatory Drugs: Population Based Observational Study and Case-Control Study,&quot; <i>BMJ</i>, 2001, 322(7281):266-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/11157526/pubmed\" target=\"_blank\" id=\"11157526\">11157526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Obase Y, Matsuse H, Shimoda T, et al, &ldquo;Pathogenesis and Management of Aspirin-Intolerant Asthma,&rdquo; <i>Treat Respir Med</i>, 2005, 4(5):325-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/16137190/pubmed\" target=\"_blank\" id=\"16137190\">16137190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo; <i>Arch Intern Med</i>, 2000, 160(6):777-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/10737277/pubmed\" target=\"_blank\" id=\"10737277\">10737277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pendeville PE, Van Boven MJ, Contreras V, et al, &quot;Ketorolac Tromethamine for Postoperative Analgesia in Oral Surgery,&quot; <i>Acta Anaesthesiol Belg</i>, 1995, 46(1):25-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/7618425/pubmed\" target=\"_blank\" id=\"7618425\">7618425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo; <i>Arch Intern Med</i>, 1993, 153(4):477-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/8435027/pubmed\" target=\"_blank\" id=\"8435027\">8435027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradhan BB, Tatsumi RL, Gallina J, et al, &ldquo;Ketorolac and Spinal Fusion: Does the Perioperative Use of Ketorolac Really Inhibit Spinal Fusion?,&rdquo; <i>Spine</i>, 2008, 33(19):2079-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/18698276/pubmed\" target=\"_blank\" id=\"18698276\">18698276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. <i>Curr Opin Rheumatol</i>. 2014;26(3):354-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/24614280 /pubmed\" target=\"_blank\" id=\"24614280 \">24614280 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toradol (ketorolac) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van den Veyver IB and Moise KJ Jr, &quot;Prostaglandin Synthetase Inhibitors in Pregnancy,&quot; <i>Obstet Gynecol Surv</i>, 1993, 48(7):493-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/8355924/pubmed\" target=\"_blank\" id=\"8355924\">8355924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>Clin Pharmacokinet</i>, 1990, 19(1):44-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/2199127/pubmed\" target=\"_blank\" id=\"2199127\">2199127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker JJ, Johnstone J, Lloyd J, et al,&quot;The Transfer of Ketorolac Tromethamine From Maternal to Foetal Blood,&quot; <i>Eur J Clin Pharmacol</i>, 1988, 34(5):509-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/3264528/pubmed\" target=\"_blank\" id=\"3264528\">3264528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walton GM, Rood JP, Snowdon AT, et al, &quot;Ketorolac and Diclofenac for Postoperative Pain Relief Following Oral Surgery,&quot; <i>Br J Oral Maxillofac Surg</i>, 1993, 31(3):158-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/8512909/pubmed\" target=\"_blank\" id=\"8512909\">8512909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wischnik A, Manth SM, Lloyd J, et al, &quot;The Excretion of Ketorolac Tromethamine Into Breast Milk After Multiple Oral Dosing,&quot; <i>Eur J Clin Pharmacol</i>, 1989, 36(5):521-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/2787750/pubmed\" target=\"_blank\" id=\"2787750\">2787750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ketorolac-systemic-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9152 Version 246.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8320258\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F49214910\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8345791\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8347268\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8349402\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8349401\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8349403\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8350484\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8350485\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8353206\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8345793\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8345784\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8352025\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8345794\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25881884\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8320263\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8346957\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8345801\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8345802\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299558\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8347281\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8349365\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8345796\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8345797\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8345800\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8350489\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8352030\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F8349372\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8349370\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8349373\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8353221\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961984\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9152|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ketorolac-systemic-patient-drug-information\" class=\"drug drug_patient\">Ketorolac (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=ketorolac-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Ketorolac (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}